Are miRNAs the key to retinal degeneration?

Article

Absence of a specific RNase III endonuclease in the retina causes no immediate structural abnormalities but does prompt total retinal inactivity, according to a study published in the May 7 2008 issue of the Journal of Neuroscience.

Absence of a specific RNase III endonuclease in the retina causes no immediate structural abnormalities but does prompt total retinal inactivity, according to a study published in the May 7 2008 issue of the Journal of Neuroscience.

Devid Damiani of the Neuroscience Institute, Pisa, Italy and colleagues removed one or both alleles of Dicer, essential for the production and function of mature miRNAs, from the retinas of mice embryos.

The mice with both Dicer alleles removed were born with fully formed retinas that displayed abnormally low electrical activity. By day 16, photoreceptor rosettes had formed; various retinal cell types continued to degenerate and scotopic and photopic responses to electroretinogram (ERG) testing decreased progressively at one, three and five months. Mice with a single allele of Dicer removed registered compromised ERG responses but retinas remained structurally sound throughout life. Retinas with depleted levels of Dicer had lower levels of several different miRNAs.

The researchers concluded that, since removing Dicer prompts gradual retinal degeneration in morphologically correct cells, it is possible that miRNAs are implicated in neurodegenerative disorders.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.